Spinal Muscular Atrophy Foundation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Spinal Muscular Atrophy Foundation
Applications to market Roche’s spinal muscular atrophy drug have already been submitted in eight countries including the US, where a decision is due in August.
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
- Academic and Research Institutions
- Other Names / Subsidiaries
- SMA Foundation